Patients with low-grade, follicular non-Hodgkin's lymphoma usually present with advanced disease, which is not considered curable with conventional therapies. New approaches are needed to improve the outcomes in patients with this disease. Yttrium 90 ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), is highly effective, with overall response rates of 73% to 83% and complete response rates of 15% to 51%, with a median duration of response in complete responders of 23 months. The response rates tend to be higher in patients who have been treated with fewer prior therapies, and 90 Y ibritumomab tiuxetan may be suitable for use early in the course of therapy. Delayed myelosuppression is the most common adverse effect, and it is predictable, reversible, and manageable. Yttrium 90 ibritumomab tiuxetan has less nonhematologic toxicity than chemotherapy, with only minimal alopecia, mucositis, nausea, or vomiting, and a lower incidence of infections. The ibritumomab tiuxetan regimen is routinely and safely given in an outpatient setting and is completed in 7 to 9 days, and is thus more convenient for patients than chemotherapy.
T
REATMENT options for relapsed nonHodgkin's lymphoma (NHL), and in particular for indolent B-cell NHL, have been expanded by the introduction of the monoclonal antibody to CD20 rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and Biogen Idec Inc, Cambridge, MA), which has gained near-universal acceptance, due in large part to its observed response rate as a single agent of up to 48%, with a median time to progression of 13 months. 1,2 Several strategies to increase the response rate and duration of response with rituximab have been evaluated, including the use of rituximab in combination with conventional chemotherapy, such as CHOP (cyclophosphamide/vincristine/doxorubicin/ prednisone), and the use of high-dose rituximab. [2] [3] [4] Radioimmunotherapy is particularly useful in B-cell lymphomas, which are highly radiosensitive. The radiolabeled monoclonal antibody yttrium 90 ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) has been shown to produce clinically significant responses in tumors of all sizes in patients with NHL, and it was the first radiolabeled monoclonal antibody approved for the treatment of lymphoma. In clinical trials, 90 Y ibritumomab tiuxetan has achieved consistent overall response rates (ORRs) of 73% to 83%, with a complete response/complete response (unconfirmed) (CR/CRu) rate of 15% to 51% (Table  1) . [5] [6] [7] [8] [9] [10] [11] [12] [13] The median duration of response in patients with a CR/CRu has been 23 months. 5 Yttrium 90 ibritumomab tiuxetan is well tolerated and has a good safety profile in the indicated population. The dose-limiting toxicity of 90 Y ibritumomab tiuxetan is a delayed but transient myelosuppression.
YTTRIUM 90 IBRITUMOMAB TIUXETAN
Yttrium 90 ibritumomab tiuxetan is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL, including patients with rituximab-refractory follicular NHL. 14 The murine IgG1 monoclonal antibody ibritumomab is the parent antibody of the chimeric monoclonal antibody rituximab. Ibritumomab has been shown to have antiproliferative effects and to induce apoptosis in vitro. It is covalently bound to the second-generation chelator tiuxetan, which forms a strong bond with the radionuclide (Fig 1) . Tiuxetan provides a highaffinity chelation site for indium 111 (for imaging) or yttrium 90 (for therapy). Yttrium 90 is a pure beta emitter with a half-life of 64 hours, a maximum energy of 2. /L to 149 ϫ 10 9 /L. The ORR in this study was 73% (CR/CRu 51%). 5 In patients with low-grade NHL the ORR was 82% (CR 26%) and in those with intermediate-grade NHL it was 43% (CR 29%). 7 The adverse events were primarily hematologic, and correlated with the extent of marrow involvement with NHL and the platelet count before treatment.
In the clinical studies of 90 Y ibritumomab tiuxetan to date, patients with a lymphomatous marrow involvement of more than 25% were excluded. Significant thrombocytopenia is of particular concern, and a lower dose of 90 Y ibritumomab tiuxetan (0.3 mCi/kg) has been found to be appropriate in patients with mild thrombocytopenia (100 ϫ 10 9 /L to 149 ϫ 10 9 /L). 10 In this open-label multicenter phase II study by Wiseman et al, 10 ORR was 83% in 30 patients, with a CR/CRu rate of 47%. 5 Therapy with 90 Y ibritumomab tiuxetan has been compared with rituximab therapy in a phase III trial in 143 patients with histologically proven relapsed or refractory follicular, low-grade, or transformed NHL. 9 Patients were randomized to one treatment with 90 Y ibritumomab regimen 0.4 mCi/kg plus infusions of rituximab 250 mg/m 2 or to rituximab 375 mg/m 2 /wk for 4 weeks. The primary endpoint in this study was ORR; responses were confirmed by a panel of independent blinded experts. The ORR in the 90 Y ibritumomab tiuxetan group was 80% and in the rituximab group was 56% (P ϭ .002). This response rate in the rituximab control group was comparable to the 48% ORR in the pivotal trial of rituximab in 166 patients. 2 The CR/CRu rate was 34% in the 90 Y ibritumomab tiuxetan group and 20% in the rituximab group (P ϭ .04).
The efficacy of 90 Y ibritumomab tiuxetan has also been evaluated in patients with rituximabrefractory follicular NHL. 13 Patients were considered to have refractory disease if they had not responded to rituximab 375 mg/m 2 /wk or if they had durations of response of less than 6 months. Ninety-five percent of the patients had follicular histology and 90% had stage III or IV disease. This group of patients had been heavily treated, with a median of four prior chemotherapy regimens (range, 1 to 9), and many (Ͼ70%) had bulkier disease (Ն5 cm) than the patients in the above- 9 This may be attributable to the higher number of prior therapies in the patients in this trial than in the previous trial (median, 4 v 2). This result suggests that 90 Y ibritumomab tiuxetan may be more effective when it is used earlier in the course of treatment. 16 
SAFETY OF 90 Y IBRITUMOMAB TIUXETAN
The ibritumomab tiuxetan regimen should be used only in appropriate patients, and the exclusion criteria should be strictly observed (Table 2) . Patients with adequate bone marrow reserves and limited bone marrow involvement are optimal candidates. The most common adverse event with 90 Y ibritumomab tiuxetan therapy is a transient but delayed myelosuppression. Unlike chemotherapy, treatment with 90 Y ibritumomab tiuxetan is not associated with severe mucositis, hair loss, or persistent or prolonged nausea or vomiting. 12 Treatment with 90 Y ibritumomab tiuxetan does not require that patients be isolated from others at any time, because those with whom patients have close contact are exposed to only minimal radiation, which is comparable to background levels. 15 
HEMATOLOGIC EVENTS
The myelosuppression with 90 Y ibritumomab tiuxetan may result in thrombocytopenia, neutropenia, and anemia. In the 349 patients in the registrational database who were treated with 90 Y ibritumomab tiuxetan, the median nadirs were absolute neutrophil count, 0.8 ϫ 10 9 /L; platelets, 41 ϫ 10 9 /L; and hemoglobin level, 105 g/L (Table  3 ). In the randomized phase III trial that compared 90 Y ibritumomab tiuxetan with rituximab alone, the nadirs for absolute neutrophil count (median, 0.9 ϫ 10 9 /L), platelets (median, 41 ϫ 10 9 /L), and hemoglobin level (median, 108 g/L) occurred at 42 to 49 days after the start of treatment, much later than the typical 10 to 14 days with chemotherapy. The myelosuppression with the ibritumomab tiuxetan regimen is, however, predictable, reversible, and manageable.
The median duration of severe hematologic toxicities (measured from the last day of grade 2 before the nadir to the first day of grade 2 after the nadir) was 27 days for the absolute neutrophil count, 23 days for the platelet count, and 15 days for the hemoglobin level. 9 The nadirs were somewhat lower in the patients with mild thrombocytopenia, who were treated with 90 Y ibritumomab tiuxetan 0.3 mCi/kg, but this was not associated with a greater incidence of infections or bleeding than in the patients with higher platelet counts (Ն150 ϫ 
NONHEMATOLOGIC EVENTS
The most common nonhematologic toxicities observed in the clinical trials of 90 Y ibritumomab tiuxetan are shown in Table 4 . These tend to reflect the nonhematologic toxicities of rituximab, and may be attributable to the preinfusions of rituximab, which account for most of the total amount of antibodies given.
INFECTIOUS EVENTS
The incidence of infectious complications in the first 3 months after the start of therapy is 29% (Table 5 ). 14 This is substantially lower than the typical incidence of infectious complications with CHOP chemotherapy of 65%. 17 These infections included febrile neutropenia, sepsis, pneumonia, cellulitis, diarrhea, osteomyelitis, and urinary tract and upper respiratory tract infections. In an integrated safety database of 349 patients the overall incidence of hospitalization because of serious infection was 7%. 14 The incidence of hospitalization because of febrile neutropenia was 2%. 12 
SECONDARY MALIGNANCIES
In a recent update reported by Czuczman et al, 18 myelodysplastic syndrome or acute myelogenous leukemia had developed in 10 (1.3%) of 770 patients treated with 90 Y ibritumomab tiuxetan over the past 9 years. The onset of a secondary cancer occurred at 4 to 34 months after treatment with 90 Y ibritumomab tiuxetan and 1.5 to 14 years after the diagnosis of NHL. The overall risk of the development of myelodysplastic syndrome/acute myelogenous leukemia reported in the literature on patients with NHL treated with chemotherapy ranges from 0.6% to 8% at 10 years. Thus far, the incidence of secondary malignancies after treatment with 90 Y ibritumomab tiuxetan is well within the range expected in patients who have previously been treated with multiple potentially leukemogenic therapies (eg, regimens containing alkylating agents). 19 Y ibritumomab tiuxetan therapy. These treatments included single alkylating agents, CHOP, and other intensive chemotherapy regimens. Some patients were treated with bioimmunotherapy or high-dose chemotherapy followed by peripheral blood stem cell Y ibritumomab tiuxetan at a single institution were no different from those in similar patients who had not been treated with 90 Y ibritumomab tiuxetan. Eight patients in this study were treated with autologous stem cell transplantation, in seven of whom peripheral blood stem cells were collected after growth factor mobilization. Bone marrow collection was required in one patient, because of low peripheral blood stem cell counts despite the use of growth factor. Another patient had an allogeneic transplant. All patients recovered adequate blood cell counts after transplantation, at rates similar to those in historical controls who had not been treated with 90 Y ibritumomab tiuxetan.
Yttrium 90 ibritumomab tiuxetan is highly effective, with ORRs of 73% to 83% and CR/CRu of 15% to 51% in clinical trials, with a median duration of response in complete responders of 23 months. Yttrium 90 ibritumomab tiuxetan may be particularly suitable for use early in the course of therapy, because the ORRs tend to be higher in patients who have been treated with fewer prior therapies. Delayed myelosuppression is the most common adverse event, and it is predictable, reversible, and manageable.
Treatment with 90 Y ibritumomab tiuxetan is better tolerated than chemotherapy, with minimal nonhematologic toxicities such as mucositis, alopecia, or severe or prolonged nausea or emesis. The incidence of infections is also lower, and the 90 Y ibritumomab tiuxetan regimen is more convenient for patients. The ibritumomab tiuxetan regimen is routinely and safely given in an outpatient setting and is completed in 7 to 9 days.
